<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860715</url>
  </required_header>
  <id_info>
    <org_study_id>GX-I7-HV-001</org_study_id>
    <nct_id>NCT02860715</nct_id>
  </id_info>
  <brief_title>Clinical Trial of GX-I7 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GX-I7 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study
      designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GX-I7
      in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects who are adequately eligible to attend this clinical trial via screening will be
      hospitalized one day prior to the injection (Day -1), administered a single dose of GX-I7
      solution for subcutaneous injection, and then discharged on Day 3. After completing all
      scheduled tests at the visit 8 (Day 28), safety-related data of each cohort will be evaluated
      by Independent Safety Monitoring Committee (SMC). Dose escalation will proceed under the
      principal investigator, medical monitor, and the sponsor's mutual approval, referring to
      SMC's evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of adverse events including laboratory abnormality after Single Subcutaneous (SC) Injection of GX-I7</measure>
    <time_frame>4 weeks</time_frame>
    <description>Adverse events after injections.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Assessment: Maximum serum concentration (Cmax)</measure>
    <time_frame>4 weeks</time_frame>
    <description>PK Parameters to be assessed by single SC administration will be Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Assessment: Time to Cmax (Tmax)</measure>
    <time_frame>4 weeks</time_frame>
    <description>PK Parameters to be assessed by single SC administration will be Tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Assessment: apparent terminal half-life (t1/2)</measure>
    <time_frame>4 weeks</time_frame>
    <description>PK Parameters to be assessed by single SC administration will be t1/2. t1/2=lnf(2)/λz (λz: invariable for speed of loss obtained from linear regression analysis in logarithmic plot of terminal phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Assessment: Area under the curve from zero to last time of measurable concentration after single administration by trapezoidal rule (AUCt)</measure>
    <time_frame>4 weeks</time_frame>
    <description>PK Parameters to be assessed by single SC administration will be AUC (0-inf).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Assessment: Area under the curve from zero to infinity (AUC(0-inf))</measure>
    <time_frame>4 weeks</time_frame>
    <description>PK Parameters to be assessed by single SC administration will be AUC(0-inf).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) Assessment: Emax of Absolute Lymphocyte Count (ALC)</measure>
    <time_frame>8 weeks</time_frame>
    <description>PD parameters will be determined by Emax of ALC, which will be compared with peripheral baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) Assessment: Area Under The Effect-Time Curve Up To Last Quantifiable Effect (AUEClast) of ALC</measure>
    <time_frame>8 weeks</time_frame>
    <description>PD parameters will be determined by AUEClast of ALC, which will be compared with peripheral baseline.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory PD (PD) assessment: Change of the ratio of immune cells</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change of the ratio of immune cells by flow cytometer</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory PD (PD) assessment: T cells in lymphocytes by flow cytometer</measure>
    <time_frame>4 weeks</time_frame>
    <description>Cluster of Differentiation 4 (CD4) T and Cluster of differentiation 8 (CD8) T in lymphocytes by flow cytometer</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-I7 20㎍/㎏ (8 subjects) / Placebo (2 subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-I7 60㎍/㎏ (8 subjects) / Placebo (2 subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-I7 180㎍/㎏ (8 subjects) / Placebo (2 subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-I7 360㎍/㎏(8 subjects) / Placebo (2 subjects)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-I7</intervention_name>
    <description>Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>IL-7-hyFc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This is the placebo of GX-I7 described above.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>GX-17 vehicle (formulation buffer)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is willing and able to give informed consent after listening character of the
             clinical trial

          2. Must be 19-45 years of age, inclusive

          3. Weight 50-100kg, BMI 18-30kg/m2

          4. Subject who is adequately able to attend the study based on medical history and
             physical exam, no clinically significant abnormality from vital sign and clinical
             laboratory values

          5. No clinical abnormality from ECG test

          6. Non-smoker (no smoking or no use of any product containing nicotine least for one
             month and negative from urine test)

        Exclusion Criteria:

          1. Suspected or confirmed malignancy, or has malignancy history

          2. Any clinically significant acute or chronic medical condition requiring care of a
             physician, in liver, biliary tract, renal, nervous system (CNS or peripheral).
             respiratory system, endocrine (diabetes, hyperlipidemia etc), cardiovascular
             (congestive heart failure, coronary artery disease, myocardial infarction etc),
             hematology, malignancy, urinary disease, mental disorder, musculoskeletal disorder,
             immune system (rheumatoid arthritis, lupus etc), otorhinolaryngologic diseases

          3. Positive to HBsAg, hepatitis C virus (HCV) Ab and HIV Ab

          4. Are considering or scheduled to undergo any surgical or dental procedure during the
             study

          5. Administered other Investigational Product (IP) by attending other clinical study or
             biological equivalent study within recent 3 months

          6. Any Serious adverse drug reaction (SAR) against vaccines or antibiotics, any medical
             history with serious allergic diseases

          7. Positive from urine drug screen or respiratory alcohol screen at medical screening or
             check-in

          8. History of alcohol, drug, or substance abuse in the past 12 months

          9. Consumption of alcohol within 48 hours prior to hospitalization

         10. Medications with antacid, analgesic, herbal treatment, vitamin, mineral (except
             maximum 4 grams of acetaminophen) hormone, steroids, insulin, hypoglycemic drug or
             other hormone substitute within 14 days before administration

         11. Planning pregnancy or donation of sperm/disagreeing proper contraception during the
             study and 3 months following IP administration

         12. Do not have veins suitable for cannulation or multiple venipunctures

         13. Any other factor that the Investigator thinks will increase subject risk with
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Lee, M.D, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minkyu Heo, M.S</last_name>
    <phone>82-31-628-3340</phone>
    <email>mkheo@genexine.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juneui Park, Ph.D.</last_name>
    <phone>82-10-3926-0787</phone>
    <email>juneui.park@genexine.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Lee, M.D., Ph.D.</last_name>
      <phone>82 10 2584 4249</phone>
    </contact>
    <contact_backup>
      <last_name>Sangwon Lee, M.D.</last_name>
      <phone>82 10 5504 0697</phone>
      <email>berserk92@snu.ac.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Kang MC, Choi DH, Choi YW, Park SJ, Namkoong H, Park KS, Ahn SS, Surh CD, Yoon SW, Kim DJ, Choi JA, Park Y, Sung YC, Lee SW. Intranasal Introduction of Fc-Fused Interleukin-7 Provides Long-Lasting Prophylaxis against Lethal Influenza Virus Infection. J Virol. 2015 Dec 9;90(5):2273-84. doi: 10.1128/JVI.02768-15.</citation>
    <PMID>26656713</PMID>
  </reference>
  <reference>
    <citation>Seo YB, Im SJ, Namkoong H, Kim SW, Choi YW, Kang MC, Lim HS, Jin HT, Yang SH, Cho ML, Kim YM, Lee SW, Choi YK, Surh CD, Sung YC. Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity. J Virol. 2014 Aug;88(16):8998-9009. doi: 10.1128/JVI.00534-14. Epub 2014 Jun 4.</citation>
    <PMID>24899182</PMID>
  </reference>
  <reference>
    <citation>Ahn SS, Jeon BY, Park SJ, Choi DH, Ku SH, Cho SN, Sung YC. Nonlytic Fc-fused IL-7 synergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis. Vaccine. 2013 Jun 12;31(27):2884-90. doi: 10.1016/j.vaccine.2013.04.029. Epub 2013 Apr 23.</citation>
    <PMID>23624092</PMID>
  </reference>
  <reference>
    <citation>Martin CE, van Leeuwen EM, Im SJ, Roopenian DC, Sung YC, Surh CD. IL-7/anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R. Blood. 2013 May 30;121(22):4484-92. doi: 10.1182/blood-2012-08-449215. Epub 2013 Apr 22.</citation>
    <PMID>23610371</PMID>
  </reference>
  <reference>
    <citation>Nam HJ, Song MY, Choi DH, Yang SH, Jin HT, Sung YC. Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant. Eur J Immunol. 2010 Feb;40(2):351-8. doi: 10.1002/eji.200939271.</citation>
    <PMID>19950168</PMID>
  </reference>
  <reference>
    <citation>Park SH, Song MY, Nam HJ, Im SJ, Sung YC. Codelivery of IL-7 Augments Multigenic HCV DNA Vaccine-induced Antibody as well as Broad T Cell Responses in Cynomolgus Monkeys. Immune Netw. 2010 Dec;10(6):198-205. doi: 10.4110/in.2010.10.6.198. Epub 2010 Dec 31.</citation>
    <PMID>21286380</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>October 13, 2017</last_update_submitted>
  <last_update_submitted_qc>October 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Dose-Limiting Toxicity (DLT)</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Pharmacokinetics</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

